457 related articles for article (PubMed ID: 9164446)
21. [Are PPAR-gamma-agonists a secure choice in treatment of overweight diabetic patients?].
Larsen PJ
Ugeskr Laeger; 2000 Aug; 162(32):4280-1. PubMed ID: 10962950
[No Abstract] [Full Text] [Related]
22. Actos (pioglitazone HCL) provides a safe, effective alternative for patients formerly taking Rezulin.
Diabetes Technol Ther; 2000; 2(2):290-1. PubMed ID: 11469274
[No Abstract] [Full Text] [Related]
23. Diabetes medicine update. Old dogs, new tricks.
Nakamoto M
Diabetes Self Manag; 2003; 20(1):14-5. PubMed ID: 12632553
[No Abstract] [Full Text] [Related]
24. Glitazones and NIDDM.
Sakane N; Yoshida T; Kondo M
Lancet; 1997 Mar; 349(9056):952. PubMed ID: 9093269
[No Abstract] [Full Text] [Related]
25. FDA reviews troglitazone.
Donnelly R
Diabetes Obes Metab; 1999 Mar; 1(2):65-6. PubMed ID: 11220513
[No Abstract] [Full Text] [Related]
26. How should patients taking the discontinued diabetes drug troglitazone be managed?
Reddy SS
Cleve Clin J Med; 2000 Jun; 67(6):401-2, 455. PubMed ID: 10860221
[No Abstract] [Full Text] [Related]
27. Hepatic injury due to troglitazone.
Malik AH; Prasad P; Saboorian MH; Thiele DL; Malet PF
Dig Dis Sci; 2000 Jan; 45(1):210-4. PubMed ID: 10695637
[No Abstract] [Full Text] [Related]
28. The rise and fall of troglitazone.
Bailey CJ
Diabet Med; 2000 Jun; 17(6):414-5. PubMed ID: 10975209
[No Abstract] [Full Text] [Related]
29. The role of troglitazone in treating the insulin resistance syndrome.
Granberry MC; Schneider EF; Fonseca VA
Pharmacotherapy; 1998; 18(5):973-87. PubMed ID: 9758309
[TBL] [Abstract][Full Text] [Related]
30. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
31. Pulmonary edema associated with troglitazone therapy.
Hirsch IB; Kelly J; Cooper S
Arch Intern Med; 1999 Aug 9-23; 159(15):1811. PubMed ID: 10448787
[No Abstract] [Full Text] [Related]
32. Effect of troglitazone on lipoprotein(a) levels in obese subjects.
Tack CJ; Smits P; DeMacker PN; Stalenhoef AF
Diabetes Care; 1999 Oct; 22(10):1752-3. PubMed ID: 10526754
[No Abstract] [Full Text] [Related]
33. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
Blonde L; Sandberg MI; Guthrie RD
Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262
[No Abstract] [Full Text] [Related]
34. Deterioration of rheumatoid arthritis with troglitazone: a rare and unexpected adverse effect.
Sakurai A; Hashizume K
Arch Intern Med; 2000 Jan; 160(1):118-9. PubMed ID: 10632316
[No Abstract] [Full Text] [Related]
35. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Krentz AJ; Bailey CJ; Melander A
BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
[No Abstract] [Full Text] [Related]
36. Conversion from troglitazone to rosiglitazone.
Bell DS; Ovalle F; Shadmany S
Endocr Pract; 2001; 7(4):326. PubMed ID: 11497487
[No Abstract] [Full Text] [Related]
37. Warner Lambert/Sankyo diabetes drug nears market.
Nat Biotechnol; 1997 Feb; 15(2):113. PubMed ID: 9035120
[No Abstract] [Full Text] [Related]
38. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Johnson MD; Campbell LK; Campbell RK
Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
[TBL] [Abstract][Full Text] [Related]
39. [Insulin sensitizer drugs--review].
Yamanouchi T
Nihon Rinsho; 2002 Sep; 60 Suppl 9():409-15. PubMed ID: 12387026
[No Abstract] [Full Text] [Related]
40. [Insulin-sensitizing agent].
Yamanouchi T
Nihon Rinsho; 1999 Mar; 57(3):675-80. PubMed ID: 10199153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
